Wednesday, 12 August 2009

Sumatriptan Succinate 25, 40 and 100 mg tablets (Imitrex): More generic players got final approvals

The following generic players have got final/tentative approval to market antimigraine formulation Sumatriptan Succinate 25, 40 and 100 mg tablets (generic version of Imitrex):

Final approvals

1. TEVA (ANDA approved on February 9, 2009)
2. RANBAXY (25 and 50 mg tablets on August 10, 2009; 100 mg on February 9, 2009)
3. DR REDDYS LABS INC (ANDA approved on August 10, 2009)
4. COBALT LABS INC (ANDA approved on August 10, 2009)
5. SANDOZ (ANDA approved on August 10, 2009)
6. ROXANE (ANDA approved on August 10, 2009)
7. ORCHID HLTHCARE (ANDA approved on August 10, 2009)
8. SUN PHARM INDS (ANDA approved on August 10, 2009)
9. AUROBINDO PHARMA (ANDA approved on August 10, 2009)
10. MYLAN (ANDA approved on August 10, 2009)

Tentative approvals

1. GENPHARM (January 24, 2007)
2. WATSON LABS (August 27, 2007)

Most of generic players got final approval on August 10, 2009.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker